MALVERN, Pa., Mar 30, 2016 – Alexar Therapeutics, Inc., a privately held specialty pharmaceutical company dedicated to the development of topical and systemic therapies based on Liver X Receptor (LXR) modulators, today announced it has changed its name to Ralexar Therapeutics, Inc., effective immediately.
Ralexar Therapeutics, Inc. is a privately held specialty pharmaceutical company founded in January 2014 and based in Malvern, Pennsylvania. The company is developing topical and systemic therapies based on LXR modulators. The initial focus for the company is on developing ALX-101 for the treatment of various cutaneous inflammatory disorders. More information can be found by visiting the company’s website at www.ralexartx.com.
Mike Beyer, Sam Brown, Inc.